Prostate cancer is a common malignancy with a heterogeneous disease course. Prior studies have identified a paucity of point mutations in protein-coding genes and only a few clinically relevant driver alterations. Here, using the Pan Prostate Cancer Group whole genome sequencing dataset from 1001 men, we perform an int...
D. Pellegrina, Daria Kiriy, Kevin C. L. Cheng et al.· Nature Communications· 1 citation
Abstract Introduction Prostate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outcomes and limited curative treatment options. Within this group, a subset of patients exhibit oligometastatic d...
S. Lichtman-Mikol, J. M. Lang, H. Nagar et al.· BMJ Open· 1 citation
The inactivation of tumour suppressor genes is a key step in cancer development, and is usually achieved by homozygous loss. In prostate cancer, however, large genomic regions are often hemizygously lost, which complicates the identification of putative tumour suppressors in these regions. Here, we develop Epi2Hit, an...
Daria Kiriy, F. Favero, C. Gerhäuser et al.· Nature Communications· 1 citation
Prostate cancer follows a long and heterogeneous disease course with incompletely understood aetiology1. Here we dissect the mutational processes shaping the genomes of 959 donors from the Pan Prostate Cancer Group and assess their clinical relevance. By integrating de novo extracted single-base substitution, insertion...
A. Gruber, A. Olsen, Bárbara Hernando et al.· Nature· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
